- Aktuelle Seite:
-
Home
-
Begleitkrankheiten
- HIV
UNAIDS. Promises to improve health outcomes for people who inject drugs remain unfulfilled as 99% do not have adequate access to harm reduction services
New report by UNAIDS highlights the urgent need to implement a human rights and evidence-informed approach to reach people who inject drugs with essential health services. (UNAIDS, Genf, 13.03.2019)
UNAIDS. HEALTH, RIGHTS AND DRUGS - HARM REDUCTION, DECRIMINALIZATION AND ZERO DISCRIMINATION FOR PEOPLE WHO USE DRUGS
(UNAIDS, 2019)
http://www.unaids.org/sites/default/files/media_asset/JC2954_UNAIDS_drugs_report_2019_en.pdf
Deutsche AIDS-Hilfe: HIV-Test
Manchmal muss man’s einfach wissen. Gerade nach einer Risikosituation ist es wichtig, Gewissheit zu haben, dass nichts passiert ist. Ein HIV-Test schafft Klarheit.
Inhalt: Überblick zum HIV-Test - Gute Gründe für den HIV-Test - HIV-Tests im Überblick - HIV-Selbsttest - Wo auf HIV testen lassen? (DAH, 2019)
https://www.aidshilfe.de/hiv-test
HIV-Patient symptomfrei nach Knochenmarktransplantation
London – Der „Berliner Patient“ Timothy Ray Brown galt bisher als weltweiter Einzelfall, der von einer HIV-Infektion geheilt werden konnte. Einer Studie in Naturezufolge könnte es nun einen zweiten Fall in London geben (2019; doi: 10.1038/s41586-019-1027-4). (aerzteblatt.de, 05.03.2019)
HIV crisis in the Philippines: urgent actions needed
Gangcuangco, Louie Mar A
The Lancet Public Health , Volume 4 , Issue 2 , e84
https://www.thelancet.com/journals/lanpub/article/PIIS2468-2667(18)30265-2/fulltext
Addressing the HIV crisis in the Philippines
Marston, Jez Lim et al.
The Lancet Public Health , Volume 4 , Issue 3 , e126
https://www.thelancet.com/journals/lanpub/article/PIIS2468-2667(19)30024-6/fulltext
International AIDS Society. Getting to the Heart of Stigma
“THE PERSISTENCE OF STIGMA IN THE CONTEXT OF HIV ALSO CAUSES IMMENSE HUMAN HARDSHIP AND DIMINISHES US AS A GLOBAL COMMUNITY.”
IAS – International AIDS Society, Annual Letter, Februar 2019-03-02
https://www.iasociety.org/Who-we-are/About-the-IAS/Annual-Letter-2019
A global meta-analysis on HIV, hepatitis C and hepatitis B among people who inject drugs - do gender differences vary by country-level indicators?
Leung J, Peacock A, Colledge S, Grebely J, Cunningham EB, Hickman M, Vickerman P, Stone J, Trickey A, Dumchev K, Lynskey M, Hines L, Griffiths P, Mattick RP, Degenhardt L, Larney S.
J Infect Dis. 2019 Feb 6. doi: 10.1093/infdis/jiz058.
Abstract
https://www.ncbi.nlm.nih.gov/pubmed/30726973
HIV risk behaviours among women who inject drugs in coastal Kenya: findings from secondary analysis of qualitative data.
Mburu G, Limmer M, Holland P.
Harm Reduct J. 2019;16(1):10. Published 2019 Feb 6. doi:10.1186/s12954-019-0281-y
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6364406/
Medikamente zur HIV-Prophylaxe: DAK-Gesundheit übernimmt Kosten für PrEP
Die DAK-Gesundheit übernimmt als erste Krankenkasse die Kosten für die sogenannte HIV-Präexpositionsprophylaxe (PrEP). Dabei handelt es sich um Medikamente, die eine HIV-Infektion verhindern können.
Die Arzneimittel werden zusammen mit anderen Arzneistoffen bereits seit Jahren genutzt, um bestehende HIV-Infektionen zu behandeln. Inzwischen sind sie auch zur Vorbeugung zugelassen, gehören jedoch nicht zu den regulären Leistungen der Krankenkassen. (DAK – Deutsche Angestellten Krankenkasse, 13.02.2019)
https://www.dak.de/dak/leistungen/hiv-prophylaxe-2037472.html
USA. Black Americans and HIV/AIDS: The Basics
Key Facts:
- Black Americans have been disproportionately affected by HIV/AIDS since the epidemic’s beginning, and that disparity has deepened over time.
- Although they represent only 12% of the U.S. population, Blacks account for a much larger share of HIV diagnoses (43%), people estimated to be living with HIV disease (42%), and deaths among people with HIV (43%) than any other racial/ethnic group in the U.S.
- Among Black Americans, Black women, youth, and gay and bisexual men have been especially hard hit.
- A number of challenges contribute to the epidemic among Blacks, including poverty, lack of access to health care, higher rates of some sexually transmitted infections and smaller sexual networks, lack of awareness of HIV status, and stigma.
- Despite this impact, recent data indicate some encouraging trends, including declining new HIV diagnoses among Blacks overall, especially among women, and a leveling off of new diagnoses among Black gay and bisexual men. However, given the epidemic’s continued and disproportionate impact among Blacks, a continued focus is critical to addressing HIV in the United States. (KFF – Kaiser Family Foundation, USA, 07.02.2019)
https://www.kff.org/hivaids/fact-sheet/black-americans-and-hivaids-the-basics
USA. The HIV/AIDS Epidemic in the United States: The Basics
Key Facts
The first cases of what would later become known as AIDS were reported in the United States in June of 1981. Today, there are more than 1.1 million people living with HIV and more than 700,000 people with AIDS have died since the beginning of the epidemic.
HIV continues to have a disproportionate impact on certain populations, particularly racial and ethnic minorities and gay and bisexual men and other men who have sex with men.
HIV testing is important for both treatment and prevention efforts. Yet, 14% of those infected with HIV are unaware they are infected.
Antiretroviral therapy (ART) has substantially reduced AIDS-related morbidity and mortality and improved long-term outcomes for people with HIV. Treatment guidelines recommend initiating treatment as soon as one is diagnosed with HIV. According to the U.S. Centers for Disease Control and Prevention (CDC), when an individual living with HIV is on antiretroviral therapy and the level of HIV in their body is undetectable, there is “effectively no risk” of sexual transmission. Still, many people with HIV are not in care, on treatment, or have their virus under control.
(...) (Kaiser Family Foundation, USA, 04.02.2019)
https://www.kff.org/hivaids/fact-sheet/the-hivaids-epidemic-in-the-united-states-the-basics
Patient and provider perspectives on implementation barriers and facilitators of an integrated opioid treatment and HIV care intervention.
Cooke A, Saleem H, Hassan S, Mushi D, Mbwambo J, Lambdin B.
Addict Sci Clin Pract. 2019 Jan 28;14(1):3. doi: 10.1186/s13722-019-0133-9.
https://ascpjournal.biomedcentral.com/articles/10.1186/s13722-019-0133-9
Performance indicator as the main and the only goal: a “dark side” of the intervention aims to accelerate HIV treatment entry among people who inject drugs in Kyiv, Ukraine
Alexandra Dmitrieva, Vladimir Stepanov, Ievgeniia-Galyna Lukash and Anna Martynyuk
Harm Reduction Journal2019, 16:8, doi.org/10.1186/s12954-019-0279-5
https://harmreductionjournal.biomedcentral.com/articles/10.1186/s12954-019-0279-5
Kanada. CHIWOS - The Canadian HIV Women’s Sexual & Reproductive Health Cohort Study / L’étude sur la santé sexuelle et reproductive des femmes vivant avec le VIH (FVVIH) au Canada
CHIWOS is committed to creating new knowledge that will be used to support women living with HIV in Canada to achieve optimal health and well-being / CHIWOS est engagé dans une démarche visant à créer des nouvelles connaissances qui seront utilisées afin de soutenir les femmes vivant avec le VIH au Canada dans l’atteinte de leur niveau optimal de santé et de bien-être. (Stand Februar 2019)
Reducing HIV-related stigma and discrimination in healthcare settings: A systematic review of quantitative evidence.
Feyissa GT, Lockwood C, Woldie M, Munn Z (2019)
PLoS ONE 14(1): e0211298. doi.org/10.1371/journal.pone.0211298
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0211298
Advances in the understanding of Mycobacterium tuberculosis transmission in HIV-endemic settings.
Peters JS, Andrews JR, Hatherill M, Hermans S, Martinez L, Schurr E, van der Heijden Y, Wood R, Rustomjee R, Kana BD.
Lancet Infect Dis. 2018 Dec 13. pii: S1473-3099(18)30477-8. doi: 10.1016/S1473-3099(18)30477-8.
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(18)30477-8/fulltext
Transmission of drug-resistant tuberculosis in HIV-endemic settings.
Khan PY, Yates TA, Osman M, Warren RM, van der Heijden Y, Padayatchi N, Nardell EA, Moore D, Mathema B, Gandhi N, Eldholm V, Dheda K, Hesseling AC, Mizrahi V, Rustomjee R, Pym A.
Lancet Infect Dis. 2018 Dec 13. pii: S1473-3099(18)30537-1. doi: 10.1016/S1473-3099(18)30537-1.
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(18)30537-1/fulltext
Understanding HIV and hepatitis C virus risk among incarcerated young men with histories of injecting drug use
Walker, Shelley et al.
The Lancet Infectious Diseases , Volume 19 , Issue 2 , 130 - 131
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(18)30801-6/fulltext
Global and regional molecular epidemiology of HIV-1, 1990–2015: a systematic review, global survey, and trend analysis
Hemelaar, JorisAbimiku, Alash'le G et al.
The Lancet Infectious Diseases , Volume 19 , Issue 2 , 143 - 155
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(18)30647-9/fulltext
EACS-HIV-LEITLINIEN - Version 9.1 - Oktober 2018 – Englisch
EACS produces the European Guidelines for treatment of HIV-positive adults in Europe. The English version is regularly updated by the guideline panels. A major update is published once per year in autumn and translated into additional languages. (European AIDS Clinical Society / EACS)
http://www.eacsociety.org/files/2018_guidelines-9.1-english.pdf
HIV. Neue EACS Leitlinien
Die Europäische Aids-Gesellschaft hat im Oktober die Leitlinien aktualisiert. Dabei folgt sie mehr denn je internationalen Trends. Hier die wichtigsten Neuerungen.(Die deutsche Übersetzung liegt noch nicht vor, Anm. Forum Substitutionspraxis) (hiv&more, Ausgabe 4/2018)
https://www.hivandmore.de/archiv/2018-4/HIV-m4_18_Akt_NeueEACSLeitlin.pdf
Increasing proportions of HIV-1 non-B subtypes and of NNRTI resistance between 2013 and 2016 in Germany: Results from the national molecular surveillance of new HIV-diagnoses.
Hauser A, Hofmann A, Meixenberger K, Altmann B, Hanke K, Bremer V, et al. (2018)
PLoS ONE 13(11): e0206234. doi.org/10.1371/journal.pone.0206234
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0206234
Influence of substance use and cognitive impairment on adherence to antiretroviral therapy in HIV+ patients.
Sánchez-Rivero I, Madoz-Gúrpide A, Parro-Torres C, Hernández-Huerta D, Ochoa Mangado E.
Adicciones. 2018 Nov 21;0(0):1025. doi: 10.20882/adicciones.1025.
(-> Download this PDF file)
http://adicciones.es/index.php/adicciones/article/view/1025/993
Behavioral and Clinical Characteristics of American Indian/Alaska Native Adults in HIV Care - Medical Monitoring Project, United States, 2011-2015.
Baugher AR, Beer L, Bradley HM, Evans ME, Luo Q, Shouse RL.
MMWR Morb Mortal Wkly Rep. 2019 Jan 4;67(5152):1405-1409. doi: 10.15585/mmwr.mm675152a1.
https://www.cdc.gov/mmwr/volumes/67/wr/mm675152a1.htm
HIV knowledge and risk behaviors among drug users in three Vietnamese mountainous provinces.
Nguyen TMT, Tran BX, Fleming M, Pham MD, Nguyen LT, Nguyen ALT, Le HT, Nguyen TH, Hoang VH, Le XTT, Vuong QH, Ho MT, Dam VN, Vuong TT, Nguyen V, Nguyen HLT, Do HP, Doan PL, Nguyen HH, Latkin CA, Ho CSH, Ho RCM.
Subst Abuse Treat Prev Policy. 2019 Jan 15;14(1):3. doi: 10.1186/s13011-019-0191-8.
https://substanceabusepolicy.biomedcentral.com/articles/10.1186/s13011-019-0191-8
Trends in cause-specific mortality in HIV-Hepatitis C co-infection following hepatitis C treatment scale-up.
Kronfli N, Bhatnagar SR, Hull MW, Moodie EEM, Cox J, Walmsley S, Gill J, Cooper C, Martel-Laferriere V, Pick N, Klein MB; Canadian Co-Infection Cohort Investigators.
AIDS. 2019 Jan 12. doi: 10.1097/QAD.0000000000002156.
Abstract -> open access -> pdf
https://pdfs.journals.lww.com/aidsonline/9000/00000/Trends_in_cause_specific_mortality_in.96993.pdf
Differences in the rate of nicotine metabolism among smokers with and without HIV.
Ashare RL, Thompson M, Leone F, Metzger D, Gross R, Mounzer K, Tyndale RF, Lerman C, Mahoney MC, Cinciripini P, George TP, Collman RG, Schnoll R.
AIDS. 2019 Jan 14. doi: 10.1097/QAD.0000000000002127.
Abstract
https://www.ncbi.nlm.nih.gov/pubmed/30649060
Live Imaging of HIV-1 Transfer across T Cell Virological Synapse to Epithelial Cells that Promotes Stromal Macrophage Infection
Real, Fernando et al.
Cell Reports , Volume 23 , Issue 6 , 1794 - 1805
https://www.cell.com/cell-reports/fulltext/S2211-1247(18)30570-9
Einige Opioide erhöhen Pneumonierisiko
New Haven/Connecticut – Die Einnahme von Opioid-Schmerzmitteln erhöht das Risiko auf eine ambulant erworbene Pneumonie. Am meisten waren in einer Fall-Kontroll-Studie in JAMA Internal Medicine(2019; doi: 10.1001/jamainternmed.2018.6101) Patienten gefährdet, die aufgrund einer HIV-Infektion eine geschwächte Immunabwehr hatten und/oder mit Opioiden behandelt wurden, die eine immunsupprimierende Nebenwirkung haben. (aerzteblatt.de, 09.01.2019)
https://www.aerzteblatt.de/nachrichten/100244/Einige-Opioide-erhoehen-Pneumonierisiko
Seite 1 von 14